Your browser doesn't support javascript.
loading
Cardiovascular health-related quality of life in cancer: a prospective study comparing the ESC HeartQoL and EORTC QLQ-C30 questionnaire.
Anker, Markus S; Potthoff, Sophia K; Lena, Alessia; Porthun, Jan; Hadzibegovic, Sara; Evertz, Ruben; Denecke, Corinna; Fröhlich, Ann-Kathrin; Sonntag, Frederike; Regitz-Zagrosek, Vera; Rosen, Stuart D; Lyon, Alexander R; Lüscher, Thomas F; Spertus, John A; Anker, Stefan D; Karakas, Mahir; Bullinger, Lars; Keller, Ulrich; Landmesser, Ulf; Butler, Javed; von Haehling, Stephan.
Affiliation
  • Anker MS; Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine CBF, Berlin, Germany.
  • Potthoff SK; Charité-University Medicine Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Lena A; German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany.
  • Porthun J; Berlin Institute of Health Center for Regenerative Therapies (BCRT), Berlin, Germany.
  • Hadzibegovic S; Charité-University Medicine Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Evertz R; German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany.
  • Denecke C; Berlin Institute of Health Center for Regenerative Therapies (BCRT), Berlin, Germany.
  • Fröhlich AK; Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine CVK, Berlin, Germany.
  • Sonntag F; Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine CBF, Berlin, Germany.
  • Regitz-Zagrosek V; Charité-University Medicine Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Rosen SD; German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany.
  • Lyon AR; Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine CVK, Berlin, Germany.
  • Lüscher TF; Norwegian University of Science and Technology, Gjøvik, Norway.
  • Spertus JA; Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine CBF, Berlin, Germany.
  • Anker SD; Charité-University Medicine Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Karakas M; German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany.
  • Bullinger L; Berlin Institute of Health Center for Regenerative Therapies (BCRT), Berlin, Germany.
  • Keller U; Department of Cardiology and Pneumology, University of Göttingen Medical Center, Göttingen, Germany.
  • Landmesser U; German Centre for Cardiovascular Research (DZHK), partner site Göttingen, Göttingen, Germany.
  • Butler J; Charité-University Medicine Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • von Haehling S; Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine CVK, Berlin, Germany.
Eur J Heart Fail ; 25(9): 1635-1647, 2023 09.
Article in En | MEDLINE | ID: mdl-37369985
AIMS: Health-related quality of life (HRQoL) is highly relevant in cancer and often assessed with the EORTC QLQ-C30. Cardiovascular HRQoL in cancer can be measured with the ESC HeartQoL questionnaire. We compared these instruments and examined their prognostic value. METHODS AND RESULTS: Summary scores for EORTC QLQ-C30 (0-100 points) and ESC HeartQoL (0-3 points) questionnaires were prospectively assessed in 290 patients with mostly advanced cancer (stage 3/4: 81%, 1-year mortality: 36%) and 50 healthy controls (similar age and sex). Additionally, physical function and activity assessments were performed. Both questionnaires demonstrated reduced HRQoL in patients with cancer versus controls (EORTC QLQ-C30: 67 ± 20 vs. 91 ± 11, p < 0.001; ESC HeartQoL: 1.8 ± 0.8 vs. 2.7 ± 0.4, p < 0.001). The instruments were strongly correlated with each other (summary scores [r = 0.76], physical [r = 0.81], and emotional subscales [r = 0.75, all p < 0.001]) and independently associated with all-cause mortality (best cut-offs: EORTC QLQ-C30 <82.69: hazard ratio [HR] 2.33, p = 0.004; ESC HeartQoL <1.50: HR 1.85, p = 0.004 - adjusted for sex, age, left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide [NT-proBNP], high-sensitivity troponin T, cancer stage/type), with no differences in the strength of the association by sex (p-interaction > 0.9). Combining both questionnaires identified three risk groups with highest mortality in patients below both cut-offs (vs. patients above both cut-offs: HR 3.60, p < 0.001). Patients with results below both cut-offs, showed higher NT-proBNP and reduced physical function and activity. CONCLUSIONS: The EORTC QLQ-C30 and ESC HeartQoL - assessing cancer and cardiovascular HRQoL - are both associated with increased mortality in cancer patients, with even greater stratification by combing both. Reduced HRQoL scores were associated with elevated cardiovascular biomarkers and decreased functional status.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Heart Failure / Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Eur J Heart Fail Journal subject: CARDIOLOGIA Year: 2023 Type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Heart Failure / Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Eur J Heart Fail Journal subject: CARDIOLOGIA Year: 2023 Type: Article Affiliation country: Germany